FDA Toughens Warnings On MRI Contrast Agents

Law360, New York (September 9, 2010, 7:11 PM EDT) -- The U.S. Food and Drug Administration will now require gadolinium-based contrast agents used during MRI procedures to carry updated warnings on their labels indicating the risk that certain patients with kidney disease could develop a potentially fatal condition.

The FDA said in a notice Thursday that the GBCAs will have to bear warnings on their labels that certain patients with kidney disease could develop a rare and potentially fatal condition known as nephrogenic systemic fibrosis connected to use of the intravenous drugs.

The gadolinium-based contrast agents...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.